@article{5dcd4c02653d4c3992d99f07b562ee4d,
title = "Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine",
abstract = "Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.",
keywords = "Acute myeloid leukemia, Decitabine, Myelodysplastic syndromes, Myelomonocytic leukemia, Risk factors, chronic",
author = "Elias Jabbour and Guillermo Garcia-Manero and Farhad Ravandi and Stefan Faderl and Susan O'Brien and Amber Fullmer and Cortes, {Jorge E.} and William Wierda and Hagop Kantarjian",
note = "Funding Information: This study was supported by research funding from EISAI Inc. Medical writing, editorial, and graphics assistance was provided by Peloton Advantage, LLC, and was funded by EISAI Inc. Funding Information: The authors thank Yvonne E. Yarker, PhD, CMPP, of Peloton Advantage LLC, for providing medical writing and editorial assistance during the preparation of this manuscript, which was funded by EISAI Inc. Funding Information: Angela Teng, MS, of EISAI Inc, conducted the statistical analyses. Dr Jabbour has received honoraria from Bristol-Myers Squibb and Novartis. Dr Ravandi has received research grants from Bayer , Bristol-Myers Squibb , Cephalon , Incyte , and Sunesis , and has performed formal advisory activities for Bayer, Cephalon, and Sunesis. Dr Cortes has received research grants from Celgene and EISAI Inc . Dr Kantarjian has received research grants from Celgene and EISAI Inc . The other authors have stated that they have no conflicts of interest.",
year = "2013",
month = apr,
doi = "10.1016/j.clml.2012.11.001",
language = "English (US)",
volume = "13",
pages = "131--138",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "2",
}